Gurkamal Chatta, MD
Medical Oncology · Buffalo, NYNPI 1114999083
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Sanofi accounts for 64.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $527 and has fallen 71.5% since, to $150 in 2024. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 10 payments — averaging $129.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$838
- Astellas Pharma US Inc$264
- Pfizer$135
- Seagen Inc.$46
- AVEO Pharmaceuticals, Inc.$15
Across 138 payments — averaging $16,560 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.2M
- E.r. Squibb & Sons, L.L.C.$310K
- Regeneron$300K
- Taiho Oncology, Inc.$212K
- Janssen Research & Development, LLC$102K
- Clovis Oncology, Inc.$96K
- plus $89K from 3 others
What the payments were for
- Consulting fees$52741%
- Food & beverage$49138%
- Education$27922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 4 | $838 |
| Astellas Pharma US Inc | 3 | $264 |
| Pfizer | 1 | $135 |
| Seagen Inc. | 1 | $46 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$634
How this compares
$1,297 in reported general payments places this provider in the 35th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 15 | $86 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Buffalo
- Ehsan MalekBuffalo$826K
- Marco DavilaBuffalo$437K
- Saby GeorgeBuffalo$234K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.